Building a Predictive Model for Market Access

Health Technology Assessment (HTA) agencies consider a wide range of evidence when evaluating drugs for reimbursement, but their appraisals do not indicate the weight or importance of individual evidence sources. Using Scottish Medicines Consortium (SMC) as a case study, we compared positive vs. negative reimbursement and analyzed the variables that led to their decisions.

Our webinar unpacks this important data to learn the key components that lead to both positive and negative reimbursement.